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Abstract
Background: The pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α), is expressed in ischemic tissue and is
known to modulate angiogenesis; however, the role of the two distinct TNF-α receptors, TNFR1 and TNFR2, in
mediating angiogenic signaling after cerebral ischemic stroke is relatively unknown.
Methods: C57BL6 mice were subject to 90 min of ischemia by temporary occlusion of the middle cerebral artery
(MCAO) and given daily intra-cerebroventricular injections of antibodies against TNFR1, TNFR2 or control IgG
(doses of 10, 50, and 100 ng/day) for 4 days following 90 min MCAO. Vascular remodeling and α5β1 and αVβ3
integrin expression were then examined in the brains of these mice after 4, 7, and 14 days post-ischemia. In
parallel in vitro studies, flow cytometry was used to determine the influence of TNF-α on proliferation and integrin
expression of human brain microvascular endothelial cells (HBMECs).
Results: The post-ischemic cerebral angiogenic response was inhibited by antibodies against TNFR1 but not
TNFR2, and this correlated with reduced endothelial proliferation and decreased α5β1 and αVβ3 integrin
expression after 4 and 7 days post-ischemia. Consistent with these findings, in vitro studies showed that TNF-α
induced endothelial proliferation and upregulation of α5β1 and αVβ3 integrins was abrogated by anti-TNFR1 but
not anti-TNFR2 antibodies in cultured HBMECs. In addition, blocking antibodies to α5β1 and αVβ3 integrins
significantly inhibited TNF-α-induced HBMEC proliferation.
Conclusions: Our results suggest that TNFR1-mediated signaling plays a critical role in triggering angiogenic
integrins and subsequent angiogenic responses following cerebral ischemia. These novel findings could form a
platform for future therapeutic strategies aimed at stimulating angiogenesis following cerebral ischemia.
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Background
Growing evidence underlines the therapeutic potential
of angiogenic processes post-stroke. Greater microvessel
density in the ischemic border correlates with longer
survival in stroke patients [1], and conversely, older pa-
tients who do much worse after stroke compared to
younger patients [2, 3] have reduced new vessel forma-
tion [4]. These results suggest that angiogenic remodel-
ing may improve cerebral perfusion and function as part
of a coordinated repair response. In a previous study
using a mouse model of focal cerebral ischemia, we
demonstrated the presence of proliferating endothelial
cells in the ischemic penumbra and found that this cor-
related with increased vessel density [5].
More recently, we described that in response to cere-
bral ischemia, vascular expression of fibronectin (Fn),
and its two receptors, α5β1 and αVβ3 integrins, were
all noticeably increased by day 4, peaked at day 7, then
declined at day 14. Interestingly, brain endothelial cell
(BEC) proliferation followed the same time-course,
suggesting a mechanistic relationship, with the Fn-
α5β1/αVβ3 integrin axis driving BEC proliferation and
angiogenesis. This is consistent with our previous work
in the chronic hypoxia model in which transgenic mice
lacking endothelial expression of α5 integrin (α5-EC-KO
mice) showed a delayed and reduced angiogenic response
to mild hypoxia [6].
Interestingly, angiogenic vessels in the ischemic pen-
umbra are often surrounded by inflammatory microglia
and macrophages [7–9], suggesting that activated micro-
glia and/or macrophages may be instrumental in pro-
moting the angiogenic response to cerebral ischemia. To
directly examine this question, in a previous study, we
exposed BEC to microglia-conditioned media in vitro
and found that a microglia-conditioned medium from
activated microglia directly promoted BEC proliferation,
and these effects are largely attributable to the microglial
cytokine TNF-α. In addition, pure TNF-α promoted BEC
proliferation in a dose-dependent manner [10].
Known as a strong immune-mediator and pro-
inflammatory cytokine, TNF-α is rapidly upregulated
in the brain after injury [11]. TNF-α interacts with two
types of cell surface receptors, TNF receptor 1 (TNFR1)
and TNFR2 [12]. TNFR1 is expressed on all cell types,
and this is a major signaling receptor for TNF-α, whereas
TNFR2 is expressed primarily by endothelial cells and
hematopoietic and some neuronal populations and medi-
ates limited biological responses [12].
TNFR1 primarily mediates apoptosis and inflammation
[13] but has also been shown to have anti-apoptotic
functions via activation of the NF-kB signaling pathway
[14–16]. In the context of stroke, TNFR1 has been
shown to mediate ischemic tolerance [17] and neuropro-
tection [18, 19] presumably through the TNFR1-NF-kB-
FLIP L pathway [20]. After permanent focal cerebral is-
chemia, TNFR1-KO mice developed significantly larger
infarct volumes compared with TNFR2-KO and wild-
type mice, suggesting that TNF-α exerts neuroprotective
effects through TNFR1 [18]. Furthermore, the inter-
action of TNF-α with TNFR1 sensitizes cerebral endo-
thelial cells to erythropoietin-induced angiogenesis [21].
Neuroprotection through TNFR2 has also been reported
[22, 23]. In addition, TNFR1 and TNFR2 have been re-
ported to play differential roles in hindlimb ischemia-
mediated arteriogenesis and angiogenesis, with TNFR1
inhibiting, but TNFR2 signaling promoting, hindlimb
ischemic-induced arteriogenesis and angiogenesis [24].
The exact mechanisms underlying such different proper-
ties of TNF-α receptors have yet to be fully determined,
but these might be explained by intrinsic differences in
endothelial cells between different organs and different
pathophysiological conditions.
In rodent models of permanent focal cerebral ische-
mia, TNF messenger RNA (mRNA) and protein levels
are elevated 4–6 h after the ischemic insult [11, 25–27].
In our earlier study of transient focal cerebral ischemia,
we noted that peak levels of TNF-α in the ischemic
brain precedes that of α5β1 and αvβ3 upregulation, and
our in vitro study showed that TNF-α stimulation pro-
moted strong upregulated expression of α5β1 and αVβ3
integrins on human brain microvascular endothelial cells
(HBMECs) [28]. This suggests that TNF-α induction
post-cerebral ischemia may be instrumental in promot-
ing expression of the α5β1 and αvβ3 integrins as part of
the angiogenic process. In light of these outstanding
questions, the goal of the current study was to deter-
mine which TNF-α receptor is involved in promoting
post-ischemic angiogenesis and whether TNF-α-α5β1/




Male C57Bl/6 mice weighing 20–25 g at the time of sur-
gery were used for all experiments. The present study
was conducted in accordance with NIH guidelines for
the care and use of animals in research and under proto-
cols approved by the Animal Care and Use Committee
of Gongli Hospital, Pudong New Area, Shanghai.
Surgical procedures
Under anesthesia, mice were placed in a stereotaxic
frame, and a 24-G stainless steel guide cannula was im-
planted 1 mm above the lateral cerebral ventricle and
fixed in place with dental acrylic, as described previously
[29]. After 1 day recovery, mice were anesthetized with
pentobarbital and underwent 90 min right middle cere-
bral artery occlusion (MCAO) followed by reperfusion
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as described previously [9]. Anti-mouseTNFR1 (R&D
Systems, Minneapolis, MN, USA) or TNFR2 (BioLegend,
San Diego, CA, USA) monoclonal antibody (each in doses
of 10, 50, and 100 ng/day) was given intracerebroventricu-
larly (i.c.v.) through a pre-implanted guide cannula into
the right lateral cerebral ventricles within 5 min after
90 min MCAO while animals were still anesthetized. Each
mouse received daily i.c.v injections consecutively for
4 days of reperfusion following 90 min MCAO. As a con-
trol, purified hamster IgG alone was injected into the lat-
eral ventricle of each mouse. Accurate placement of the
injection or needle track was verified at the time of dissec-
tion. Mice were euthanized 4, 7, or 14 days post-ischemia.
Immunofluorescent studies and antibodies
Mice at different time-points of reperfusion were eutha-
nized by perfusion with ice-cold saline, and the brains rap-
idly dissected and stored at −80 °C. As we previously
described [5], TTC staining was performed to demarcate
the cerebral infarct and ischemic penumbra. Immuno-
fluorescent (IF) studies were performed as previously de-
scribed [30] on 10-μm-thick frozen coronal sections. The
following monoclonal antibodies from BD Pharmingen (La
Jolla, CA, USA) were used in this study: FITC-conjugated
rat anti-mouse CD31 (PECAM-1) (clone MEC13.3; 1:100)
and PE-conjugated rat anti-mouse α5(CD49e) (clone
5H10-27; 1:100). The rabbit anti-fibronectin (F3648) was
purchased from Sigma (St. Louis, MO, USA; 1:400). The
rabbit anti-Ki67 (ab15580) was obtained from Abcam
(Cambridge, MA, USA; 1:800). The rabbit anti-CD31
(PECAM-1) (250590) antibody was obtained from Abbiotec
(San Diego, CA, USA; 1:200). The rabbit anti-integrin β3
(MBS8508681) antibody was purchased from MyBioSource
(San Diego, CA, USA; 1:200). The Alexa Fluor 488-
conjugated goat anti-rat and anti-rabbit, and Cy-3-con-
jugated goat anti-rat and anti-rabbit secondary antibodies
were obtained from EarthOx (Millbrae, CA, USA).
Cell culture
Primary human brain microvascular endothelial cells
(HBMECs) were purchased from Cell Systems (Kirkland,
WA, USA). Cells were grown on six-well plates pre-
coated with type I collagen (10 μg/ml, Sigma, for 2 h at
37 °C). The culture medium was endothelial basal
medium (EBM-2) (Lonza, CC-3156) supplemented with
10 % FBS (Gibco), ascorbic acid, L-glutamine, penicillin/
streptomycin, and human basic fibroblast growth factor
(bFGF) (all from Sigma). Cells were maintained in a hu-
midified incubator at 37 °C and 5 % CO2, and the
medium was changed every 48 h.
CFSE staining and cell proliferation
As previously described [31], HBMECs (107 cells/ml)
were labeled with carboxy-fluorescein succinimidyl ester
(CFSE; BD Biosciences, San Jose, CA, USA), for 10 min
at 37 °C with 5 μM CFSE in serum-free RPMI 1640
medium. The labeling reaction was stopped by the
addition of ice-cold complete RPMI 1640 medium at 4 °C
for 5 min, followed by centrifugation at 1000 rpm for
5 min. To assess cell proliferation, 2 × 104 CFSE-labeled
HBMECs were seeded in six-well plates pre-coated with
type I collagen (Sigma) and cultured until ~50 % conflu-
ent. For investigation of TNF-α, recombinant human TNF
(rhTNF)-α (R&D Systems, Minneapolis, MN, USA) was
added to the HBMEC cultures to a final concentration of
10 ng/ml. The same volume of saline with DMSO vehicle
was used as control. To inhibit TNF-α receptor function,
neutralizing antibodies (R&D Systems) to TNFR1 or
TNFR2 (BioLegend, San Diego, CA, USA) were added to
the HBMEC cultures at 10 μg/ml for 30 min prior to
stimulation with rhTNF-α. To examine the role of specific
integrins in promoting HBMEC proliferation, the
HBMECs were pre-incubated with mouse anti-human in-
tegrin α5, αVβ3 (both from Millipore, Temecula, CA,
USA), or a combination of both monoclonal antibodies at
5 μg/ml for 30 min prior to stimulation with rhTNF-α.
The co-cultures were incubated for 24 h. The cells were
then harvested, washed twice, re-suspended in FACS buf-
fer, and analyzed using a FACS Canto II flow cytometry
(FCM; BD, USA) by acquiring a minimum of 20,000
events from each sample. The cells were excited by a 488-
nm argon ion laser and analyzed at 530 nm (showing
CFSE). The flow cytometry data files were analyzed using
the Proliferation Wizard module of the ModFit software
(Verity Software House, USA). The proliferation index
was calculated as the sum of cells in all generations di-
vided by the number of original parent cells and expressed
as the percentage of the control.
Determination of integrin expression by flow cytometry
Confluent HBMECs were cultured in collagen-coated
six-well plates and treated with or without rhTNF-α
(R&D Systems) at 10 ng/ml for 24 h before flow cytome-
try analysis. To determine the effects of blocking anti-
bodies on HBMEC integrin expression, neutralizing
antibodies to TNFR1 or TNFR2 were added to the
HBMEC cultures at 10 μg/ml for 30 min prior to stimu-
lation with rhTNF. Integrin expression of HBMECs was
examined as described previously [32]. Briefly, cells were
labeled with anti-human α5-PE (BD), anti-human β1-PE
(BD), anti-human αV-PE (Abcam, Cambridge, MA,
USA) or anti-human β3-PE (eBioscience, San Diego, CA,
USA). Mouse IgG1-PE isotype (Abcam) or k-PE isotype
(eBioscience) was used as control antibody. Samples
were analyzed by flow cytometry, and the mean fluores-
cent intensity (MFI) of labeled cells was analyzed by Cell
Quest software. Expression level of each integrin subunit
was shown as a percent change from the control value.
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Quantification and statistical analysis
Quantification of the number of blood vessels positive
for the different antigens was performed by capturing
images of the region of interest (ischemic penumbra in-
cluding the cortex and striatum) with a ×20 objective on
a Leica TCS SP5 II microscope. These images were used
to determine the number of positive events per field of
view (FOV). For each antigen, three brain sections were
taken from each animal and matched between animals
so that the approximate position of sections used was
equivalent between different experimental conditions.
Three images were taken from cortex and striatum of
each brain section and quantified by eye for the number
of positive events per FOV. The total number of
antigen-positive events per FOV in each of regions (cor-
tex and striatum) was averaged together to represent the
number for each section. These averages of three brain
sections were used for statistical analysis for each ani-
mal. Each experiment was performed with five different
animals per condition, and the results expressed as the
mean ± SEM of the number of antigen-positive event per
FOV. The in vitro assays of cell proliferation and flow
cytometry were performed in duplicate a minimum
number of four times, and the results presented as the
mean ± SEM. Statistical significance was assessed by t
test or repeated-measures of two-way analyses of vari-
ance (ANOVA); and a Bonferroni post hoc test was used
to test multiple comparisons. All statistical analyses were
performed in SPSS (version 16.0; SPSS, Chicago, IL,
USA), and the significance was defined as P < 0.05.
Results
Blocking TNFR1 function early following cerebral ischemia
reduces angiogenic remodeling in the ischemic
penumbra
In this study, we employed the mouse model of tempor-
ary focal cerebral ischemia, in which, C57BL/6 mice are
subject to 90 min of ischemia by temporary occlusion of
the middle cerebral artery (MCAO). As previous work
has shown that TNF-α mRNA and protein levels are ele-
vated 4–6 h after ischemic insult [11, 25–27] and peak
between days 1 and 2 [28], we administered daily i.c.v.
injections of neutralizing antibodies against TNFR1 or
TNFR2 or control IgG (at doses of 10, 50, and
100 ng/day) for the first 4 days following 90 min
MCAO, to clarify which TNF receptor is mediating
post-ischemic angiogenesis.
After 4 days i.c.v. injections, some of the stroke mice
were euthanized to do TTC staining. At the lowest anti-
body concentration (10 ng/day), there was no significant
difference between infarction volumes in TNFR1,
TNFR2 antibody-injected mice, or the control group.
However, at higher antibody doses (50 and 100 ng/day),
mice receiving TNFR1 antibody showed larger infarct
size than mice receiving TNFR2 antibody or control
antibody. This finding is consistent with the study of
Lambertsen KL et al., who reported that after permanent
focal cerebral ischemia, TNFR1-KO mice developed sig-
nificantly larger infarct volumes compared with TNFR2-
KO and wild-type mice [18].
As our previous work showed that BECs start to pro-
liferate in the ischemic penumbra as early as 1 day post-
ischemia and reach a maximum mitotic level at day 7,
before declining at day 14, but that the newly formed
vessels persist at least until day 14 post-ischemia [9], we
looked for differences in the angiogenic response at 4, 7,
and 14 days following MCAO. Using CD31 labeling as
an index of blood vessel density, we found that daily in-
jection of TNFR1 antibody (50 and 100 ng/day), but not
TNFR2 antibody, noticeably reduced blood vessel dens-
ity in the ischemic penumbra compared with controls
over the 14 days following MCAO (Fig. 1a).
According to the two-way repeated-measures ANOVA,
the effect of treatment (antibodies against TNFR1, TNFR2,
or control IgG) (DF = 6; F = 5.06; P < 0.001) and time (day
4, 7, or 14) (DF = 2; F = 44.00; P < 0.001) were highly sig-
nificant. The interaction of the variables “time and treat-
ment” was not significant (DF = 12; F = 0.54; P = 0.88).
The Bonferroni post hoc test revealed that blood vessel
density (CD31-positive vessels per FOV) in the ischemic
penumbra in TNFR1 antibody-injected mice (50 and
100 ng/day for 4 days) was significantly less than that of
controls during the 14 days reperfusion following MCAO
(50 ng group: 63.1 ± 4 vs. 80.9 ± 5.7, P < 0.05; 100 ng
group: 60.1 ± 5 vs. 80.9 ± 5.7, P < 0.01). However, the
TNFR2 antibody had no appreciable effect on vessel dens-
ity. These studies suggest that TNFR1 but not TNFR2
plays a role in mediating the angiogenic response after
cerebral ischemia.
The mitogenic response to cerebral ischemia is mediated
through TNFR1 not TNFR2
We next examined whether the effect of the TNFR1
antibody in reducing vessel density in the post-ischemic
penumbra might be a result of reduced endothelial pro-
liferation. According to the two-way repeated-measures
ANOVA, the effect of treatment (antibodies against
TNFR1, TNFR2, or control IgG) (DF = 6; F = 10.21;
P < 0.001) and time (day 4, 7 or 14) (DF = 2; F = 282.40;
P < 0.001) were highly significant. The interaction of
the variables “time and treatment” was also significant
(DF = 12; F = 2.61; P < 0.01). As shown in Fig. 2, the
Bonferroni post hoc test showed that after 4 or 7 days
reperfusion following 90 min MCAO, the number of
dual-positive Ki67+/CD31+ cells per FOV in the ischemic
penumbra of TNFR1 antibody-injected mice (50 and
100 ng/day groups) was significantly lower than in control
mice (50 ng group: 5.7 ± 0.6 vs. 8.5 ± 0.6, P < 0.05 at day 4,
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9.5 ± 1.0 vs. 14.6 ± 1.1, P < 0.001 at day 7; 100 ng group:
5.5 ± 0.6 vs. 8.5 ± 0.6, P < 0.05 at day 4, 9.1 ± 1.1 vs. 14.6 ±
1.1, P < 0.001 at day 7). The number of Ki67+/CD31+
positive events under all conditions had reduced to almost
baseline levels 14 days following reperfusion. In contrast
to the TNFR1 antibody, the TNFR2 antibody had no ap-
preciable effect on the number of Ki67+/CD31+-positive
cells. These results demonstrate that the TNFR1 antibody
reduced the endothelial mitogenic response to cerebral is-
chemia, suggesting a role for TNFR1 but not TNFR2 is
mediating ischemic-induced endothelial proliferation.
TNF-α promotes brain endothelial proliferation via TNFR1
not TNFR2
As our in vivo studies showed that neutralization of
TNFR1 attenuated the post-ischemic angiogenic re-
sponse, we next examined in vitro whether TNFR1 is
directly involved in mediating TNF-α-induced endothe-
lial proliferation. Primary cultures of human brain
microvascular endothelial cells (HBMECs) were treated
with neutralizing antibodies specific for TNFR1 or
TNFR2 prior to stimulation with rhTNF-α before cell
proliferation was quantified by FACS CantoII flow
cytometry (FCM) and analyzed by ModFit software as
described in “Methods”. As shown in Fig. 3, blockade of
TNFR1 but not TNFR2 inhibited TNF-α-induced HBMEC
proliferation, suggesting that TNFR1 is responsible for
mediating TNF-α-induced HBMEC proliferation.
TNF-α-induced upregulation of α5β1 and αVβ3 integrin
expression on HBMECs is mediated through TNFR1 not
TNFR2
We have previously shown that TNF-α stimulates upreg-
ulation of α5β1 and αVβ3 integrins on HBMECs [28].
To determine which TNF receptor mediates this effect,
HBMECs were treated with antibodies specifically
against TNFR1 or TNFR2 prior to stimulation with
rhTNF-α, and 24 h later, α5β1 and αVβ3 integrin expres-
sion was analyzed by flow cytometry. As shown in Fig. 4,
compared to control conditions, rhTNF-α significantly
increased HBMEC expression of the α5, β1, αV, and β3
integrin subunits (P < 0.01), and this effect was signifi-
cantly inhibited by the anti-TNFR1 but not the anti-
TNFR2 blocking antibody (P < 0.05). This data strongly
suggests that TNFR1 mediates TNF-α-induced upregula-
tion of HBMEC α5β1 and αVβ3 integrin expression.
Fig. 1 Pharmacological blockade of TNFR1, but not TNFR2, reduced the angiogenic response in the cerebral ischemic penumbra. Frozen sections
of ischemic penumbra taken from mice after 4, 7, or 14 days reperfusion following 90 min MCAO and having received daily i.c.v. injections of
antibodies against TNFR1 or TNFR2 or control IgG, were stained for the endothelial-specific marker CD31 (AlexaFluor-488). a Daily injection
TNFR1 antibody (50 ng/day), but not TNFR2 antibody, noticeably reduced CD31 positive blood vessel density in the ischemic penumbra com-
pared with controls over the 14 days following MCAO. Scale bar = 100 μm. b Quantification of CD31+ vessels, in which each experiment was
performed with five different animals at different time-points post-ischemia. The results are expressed as the mean ± SEM of the number of
CD31+ vessels per FOV. Note that the anti-TNFR1 antibody (at doses of 50 and 100 ng/day), but not the anti-TNFR2 antibody, significantly re-
duced post-ischemic increases in vessel density in the ischemic penumbra following 14 days reperfusion. *P < 0.05, **P < 0.01 versus control
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Signaling through TNFR1 but not TNFR2 mediates the
upregulation of endothelial α5β1 and αVβ3 integrins
after cerebral ischemia
In prior studies, we have demonstrated that cerebral is-
chemia induces upregulation of vascular fibronectin, and
its two endothelial receptors α5β1 and αVβ3 integrins
[9]. As our in vitro studies above suggest that TNF-α in-
duction of α5β1 and αVβ3 integrins is mediated through
the TNFR1 pathway, we next examined this process in
vivo. According to the two-way repeated-measures
ANOVA, the effect of treatment (antibodies against
TNFR1, TNFR2, or control IgG) and time (day 4, 7, or
14) were highly significant for both α5 (treatment: DF = 6;
F = 4.17; P < 0.01; time: DF = 2; F = 27.28; P < 0.001) and
β3 (treatment: DF = 6; F = 3.84; P < 0.01; time: DF = 2; F =
98.19; P < 0.001) integrin-positive vessels. The interaction
of the variables “time and treatment” was not significant
for both α5 (DF = 12; F = 0.29; P = 0.99) and β3 (DF = 12;
F = 0.66; P = 0.78) integrin-positive vessels. As shown in
Figs. 5 and 6, the Bonferroni post hoc test showed that
after 4 or 7 days reperfusion following MCAO, the num-
ber of α5 and β3 integrin-positive vessels in the ischemic
penumbra of mice receiving the TNFR1 antibody (at doses
of 50 and 100 ng/day) was significantly lower than control
mice (for the 50 ng group: 22.3 ± 2.2 vs. 30.6 ± 2.7, P < 0.05
at day 4 for α5, 13.4 ± 1.4 vs. 19.7 ± 2.1, P < 0.05 at day 4
for β3, 27.6 ± 2.8 vs. 37.7 ± 3.2, P < 0.05 at day 7 for α5,
16.9 ± 1.4 vs. 23.8 ± 2.4, P < 0.05 at day 7 for β3; for the
100 ng group: 21.9 ± 2.4 vs. 30.6 ± 2.7, P < 0.05 at day 4
for α5, 13.2 ± 1.6 vs. 19.7 ± 2.1, P < 0.05 at day 4 for β3,
26.5 ± 3 vs. 37.7 ± 3.2, P < 0.05 at day 7 for α5, 16.1 ± 1.6
vs. 23.8 ± 2.4, P < 0.05 at day 7 for β3). The number of
α5/β3 integrin-positive vessels under all conditions had
reduced to almost baseline levels 14 days following reper-
fusion. In contrast to the TNFR1 antibody, the TNFR2
antibody had no appreciable effect on the number of α5/
β3 integrin-positive vessels. These results suggest that sig-
naling through TNFR1 but not TNFR2 is responsible for
the upregulation of α5β1 and αVβ3 integrins on brain
endothelial cells following cerebral ischemia.
Neutralization of α5β1 and αVβ3 integrins blocks
TNF-α-induced HBMEC proliferation
Our findings have demonstrated that TNF-α induces
parallel increases in HBMEC proliferation and expres-
sion of α5β1 and αVβ3 integrins. In our previous in vivo
study, we found that vascular expression of fibronectin
and theα5 and β3 integrins in the ischemic penumbra
were all significantly increased by day 4, peaked at day 7,
then declined at day 14. Interestingly, brain endothelial
cell proliferation follows exactly the same time-course,
suggesting a mechanistic relationship, with the Fn-α5β1/
αVβ3 integrin axis driving brain endothelial cell prolifer-
ation and angiogenesis [9]. These results indicate that
the brain endothelial cell proliferation induced by TNF-
α is at least partially due to the increased surface expres-
sion of the integrins. If this is true, one would expect to
see attenuated brain endothelial cell proliferation when
the α5β1 and αVβ3 functions are blocked. To test this
hypothesis, HBMEC proliferation was performed in the
presence or absence of function-blocking antibodies to
α5β1, αVβ3, or a combination of both integrins prior to
stimulation with rhTNF-α. As shown in Fig. 7, HBMEC
proliferation was significantly inhibited by the α5- or
αVβ3-blocking antibodies (P < 0.01, or P < 0.05 vs. con-
trol) and further reduced by the combination of α5 and
Fig. 2 Pharmacological blockade of TNFR1, but not TNFR2, reduced
endothelial cell proliferation in the cerebral ischemic penumbra. a
Frozen sections of ischemic penumbra taken from mice after 4, 7, or
14 days reperfusion following 90 min MCAO and having received
daily i.c.v. injections of antibodies against TNFR1 or TNFR2 or control
IgG, were dual-stained for CD31 (AlexaFluor-488) and the proliferation
marker Ki67 (Cy-3). Scale bar = 100 μm. b Quantification of CD31/Ki67
(white arrowheads in a) dual-positive proliferating BECs, in which each
experiment was performed with five different animals at different
time-points post-ischemia. The results are expressed as the mean ± SEM
of the number of CD31/Ki67 dual-positive cells per FOV. Note that
the anti-TNFR1 antibody (at doses of 50 and 100 ng/day), but not
the anti-TNFR2 antibody, resulted in significantly reduced endothelial
proliferation in the penumbra at 4 and 7 days post-ischemia. *P < 0.05,
***P < 0.001 versus control
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αVβ3 antibodies together (P < 0.01). Based on these re-
sults, we conclude that both α5β1 and αVβ3 integrins
play an important role in TNF-α-induced endothelial
cell proliferation.
Discussion
A role for TNF-α in ischemic tissue injury and neurotox-
icity is well known [33], whereas the role of the two dis-
tinct TNF-α receptors in mediating angiogenic signaling
after cerebral ischemic stroke is relatively unexplored. In
this study, we defined which TNF receptor is involved in
promoting angiogenesis after cerebral ischemia and also
examined the role of the downstream angiogenic integrins
α5β1 and αVβ3 in mediating this process. Our main find-
ings were as follows: (i) blockade of TNFR1 but not
TNFR2 reduced post-ischemic angiogenic remodeling, as
shown by reduced endothelial proliferation and reduced
vascular density in the ischemic penumbra, (ii) blockade
of TNFR1 but not TNFR2 also reduced expression of the
α5β1 and αVβ3 integrins on blood vessels in the ischemic
penumbra, (iii) TNF-α stimulation of HBMEC cell prolif-
eration and α5β1 and αVβ3 integrin expression is mediated
Fig. 3 TNF-α promotes HBMEC proliferation through TNFR1, but not TNFR2. CFSE-labeled HBMECs were pre-incubated with 10 μg/ml neutralizing
antibodies to TNFR1 or TNFR2 for 30 min and then stimulated with or without 10 ng/ml rhTNF-α. The cultures were incubated for 12 or 24 h before
being harvested and analyzed for cell proliferation by flow cytometry. a Histogram of HBMEC proliferation with indicated treatments analyzed by
ModFit software. b Quantification of HBMEC proliferation. The proliferation index was quantified using ModFit software and expressed as the
percentage of the control. The results represent the mean ± SEM of four experiments. Note that TNF-α significantly increased HBMEC proliferation
relative to control conditions (**P < 0.01); and this was abrogated by the anti-TNFR1 but not the anti-TNFR2 antibody. #P < 0.05
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through TNFR1 but not TNFR2, and (iv) α5β1 and αVβ3
integrin signaling is required for TNF-α-induced HBMEC
proliferation. Taken together, these data highlight an im-
portant role for TNFR1 in orchestrating vascular remodel-
ing events in the ischemic penumbra following cerebral
ischemia, and point to the endothelial integrins α5β1 and
αVβ3 as key mediators of this response.
Signaling through TNFR1 mediates angiogenesis after
cerebral ischemia
Several studies suggest that the neuroprotective effect of
TNF-α following stroke is mediated through TNFR1 [18,
34–37]. Taoufik and colleagues found that after focal
cerebral ischemia, TNF protects by activating the NF-
kB-FLIPL signaling pathway downstream of TNFR1, and
it can also act directly on endothelial cells to induce
angiogenesis through activation of the well-known an-
giogenic factor vascular endothelial growth factor
(VEGF) [38, 39]. Consistent with these reports, the work
presented here shows that blocking signaling via TNFR1
but not TNFR2 early following cerebral ischemia sup-
pressed the ensuing angiogenic response. In parallel in
vitro studies, TNF-α induction of brain endothelial cell
proliferation was abrogated by antibody blockade of
Fig. 4 TNF-α-induced upregulation of HBMEC integrins is mediated through TNFR1, but not TNFR2. The HBMECs were pre-incubated with 10 μg/ml
neutralizing antibodies to TNFR1 or TNFR2 for 30 min and then stimulated with or without 10 ng/ml rhTNF-α. The cultures were incubated for
12 or 24 h before being harvested and analyzed for expression of α5β1 and αVβ3 integrins by flow cytometry (a). Integrin subunit α5 is shown
in (a). b Quantification of α5β1 and αVβ3 integrin expression on HBMECs. For each integrin subunit, the mean fluorescent intensity (MFI) was
measured and expression shown as a percentage of the control values. All points represent the mean ± SEM of four experiments. Note that
TNF-α significantly increased HBMEC expression of the α5β1 and αVβ3 integrins relative to control (**P < 0.01), and this effect was abrogated by
the anti-TNFR1 antibody but not the anti-TNFR2 antibody. #P < 0.05
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TNFR1 but not TNFR2, further supporting the concept
that TNF-α promotes angiogenesis through TNFR1, not
TNFR2.
Interestingly, outside the CNS, in a model of hindlimb
ischemia, it has been reported that TNFR1 inhibits, but
TNFR2 signaling promotes, TNF-α-induced arteriogen-
esis and angiogenesis [24]. Furthermore, in a myocardial
infarct model, TNFR1-mediated signaling has a deleteri-
ous effect while TNFR2-mediated signaling is protective
and promotes repair and regeneration processes [40].
The molecular basis for these apparent differences is
currently unclear, but possible explanations might be re-
lated to organ-specific microenvironments or patho-
logical models used, and it is well known that the
angiogenic effect of TNF-α varies with different cell lines
and experimental conditions [41–43]. Another reason
may relate to the degree of ischemia employed. Our
model of MCAO is only temporary (90 min), but the
hindlimb ischemia model represents a permanent state
of severe ischemia, and it is possible that TNFR2
Fig. 5 Pharmacological blockade of TNFR1, but not TNFR2, reduced
vascular expression of α5 integrin in the cerebral ischemic penumbra.
Frozen sections of ischemic penumbra taken from mice after 4, 7, or
14 days reperfusion following 90 min MCAO and having received daily
i.c.v. injections of antibodies against TNFR1 or TNFR2 or control IgG, were
dual-stained with antibodies against CD31 (AlexaFluor-488) and α5 integrin
(Cy-3). a After 4 days reperfusion following MCAO, vascular expression
of the α5 integrin in the ischemic penumbra of mice receiving the
TNFR1 but not TNFR2 antibody (at dose of 50 ng/day) was significantly
lower than control mice. Scale bar = 100 μm. b Quantification of α5
integrin-positive vessels, in which each experiment was performed with
five different animals at different time-points post-ischemia. Results are
expressed as the mean ± SEM of the number of α5 integrin-positive
vessels per FOV. Note that the anti-TNFR1 antibody (at doses of 50 and
100 ng/day), but not the anti-TNFR2 antibody, significantly reduced
endothelial expression of the α5 integrin in the ischemic penumbra at
4 and 7 days post-ischemia. *P < 0.05 versus control
Fig. 6 Pharmacological blockade of TNFR1, but not TNFR2, reduced
vascular expression of β3 integrin in the cerebral ischemic penumbra.
Frozen sections of ischemic penumbra taken from mice after 4, 7, or
14 days reperfusion following 90 min MCAO and having received daily
i.c.v. injections of antibodies against TNFR1 or TNFR2 or control IgG,
were dual-stained with antibodies against CD31 (AlexaFluor-488) and β3
integrin (Cy-3). a After 4 days reperfusion following MCAO, vascular ex-
pression of the β3 integrin in the ischemic penumbra of mice receiving
the TNFR1 but not TNFR2 antibody (at dose of 50 ng/day) was signifi-
cantly lower than control mice. Scale bar = 100 μm. b Quantification of
β3 integrin-positive vessels, in which each experiment was performed
with five different animals at different time-points post-ischemia.
Results are expressed as the mean ± SEM of the number of β3
integrin-positive vessels per FOV. Note that the anti-TNFR1 antibody
(at doses of 50 and 100 ng/day), but not the anti-TNFR2 antibody,
significantly reduced endothelial expression of β3 integrin in the ischemic
penumbra at 4 and 7 days post-ischemia. *P < 0.05 versus control
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signaling is activated only in response to severe ischemia
[24]. Alternatively, it is worth considering that the hind-
limb ischemia and MI models used genetic mouse KOs
of TNFR1 and TNFR2, while our studies employed the
use of neutralizing antibodies [24, 40].
Signaling through TNFR1 is required for upregulation of
α5β1 and αVβ3 integrins on brain endothelial cells after
cerebral ischemia
TNF-α has been shown to significantly increase both
the cell surface and total cellular expression of αVβ3
integrins on bovine pulmonary artery endothelial cells
[44] as well as induce β1 activation and significantly
increase α5β1 integrin expression on the surface of
human umbilical vein endothelial cells (HUVECS)
[45]. This is consistent with our earlier work showing
that TNF-α stimulates upregulation of α5β1 and
αVβ3 integrin expression on HBMECs [28]. However,
it was previously unknown which TNFR mediated
this effect. Our present study provides strong evi-
dence that signaling through TNFR1 but not TNFR2
is essential for the upregulation of both α5β1 and
Fig. 7 TNF-α-induced HBMEC proliferation was abrogated by antibody neutralization of the α5 or αVβ3 integrins. CFSE-labeled HBMECs were
pre-incubated with neutralizing antibodies (5 μg/ml) against the human integrin α5 or αVβ3 integrins, or a combination of both for 30 min and
then stimulated with or without 10 ng/ml rhTNF-α for an additional 24 h before being harvested and analyzed for cell proliferation by flow
cytometry. a Histogram of HBMEC proliferation with indicated treatments analyzed by ModFit software. b Quantification of HBMEC proliferation.
The proliferation index was quantified using ModFit software and expressed as the percentage of the control. The results represent the mean ± SEM of
four experiments. Note that TNF-α significantly increased HBMEC proliferation relative to control conditions (**P < 0.01); and this was abrogated by
either anti-α5, anti-αVβ3, or a combination of both antibodies. #P < 0.05, ##P < 0.01 versus positive control
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αVβ3 integrins on brain endothelial cells after cerebral
ischemia.
α5β1 and αVβ3 integrins are critical for TNF-α-induced
cell proliferation
Extracellular matrix (ECM) proteins play an essential
role in angiogenesis. In particular, Fn and its integrin re-
ceptors are indispensable, as shown by failure of angiogen-
esis in mutant mice lacking Fn [46] or the Fn-specific
receptor, α5β1 integrin [47]. In previous studies, we
showed that cerebral hypoxia and cerebral ischemia in-
duce a strong angiogenic response in the brain, which cor-
relates with induction of fibronectin and its two receptors,
α5β1 and αVβ3 integrins on angiogenic cerebral vessels
[5, 6, 9, 48, 49]. Interestingly, in both these models, BEC
proliferation followed exactly the same time-course as the
upregulated expression of fibronectin and its receptors,
the α5β1 and αVβ3 integrins on blood vessels [9]. Further-
more, in the chronic hypoxia model, we found that trans-
genic mice lacking endothelial expression of α5 integrin
(α5-EC-KO mice) showed a delayed and reduced angio-
genic response to mild hypoxia [6]. Taken together, these
results indicate that the fibronectin-α5β1/αVβ3 integrin
axis drives BEC proliferation and angiogenesis following
cerebral hypoxia or ischemia.
Conclusions
The aim of this study was to define which TNF receptor
is involved in promoting angiogenesis after cerebral is-
chemia and investigate the potential role of the endothe-
lial integrins α5β1 and αVβ3 in mediating this process.
Our results suggest that TNFR1, but not TNFR2-
mediated signaling, plays a critical role in promoting an-
giogenic responses following cerebral ischemia and, fur-
thermore, that the angiogenic integrins α5β1 and αVβ3
are important mediators of this effect. These novel find-
ings could form the basis for future therapeutic strategies
aimed at stimulating angiogenesis following cerebral
ischemia.
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